Redhill Biopharma Ltd. (RDHL) SEC Filing 20-F Annual report for the fiscal year ending Monday, December 31, 2012

Redhill Biopharma Ltd.

CIK: 1553846 Ticker: RDHL

View differences made from one year to another to evaluate Redhill Biopharma Ltd.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 20-F Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Redhill Biopharma Ltd..


Assess how Redhill Biopharma Ltd.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Redhill Biopharma Ltd.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2013 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors



Material Contracts, Statements, Certifications & more

Redhill Biopharma Ltd. provided additional information to their SEC Filing as exhibits

Ticker: RDHL
CIK: 1553846
Form Type: 20-F Annual Report
Accession Number: 0001144204-13-009918
Submitted to the SEC: Tue Feb 19 2013 12:25:37 PM EST
Accepted by the SEC: Tue Feb 19 2013
Period: Monday, December 31, 2012
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: